Overview
Updated 14 Jul 2026
Patrick A. Ott, MD, is Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute, Boston, MA. The public record shows 616 publications with 41,494 citations (h-index 82), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune cells in cancer. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 12 companies, 1 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2026 · Nature biotechnology
- Top research focus: Cancer Immunotherapy and Biomarkers
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 206.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Sponsor: Compass Therapeutics
InvestigatorPhase 1RecruitingNCT06150664 - NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 1Active, not recruitingNCT04930783 - Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 1Active, not recruitingNCT03929029
Industry payments
Updated 14 Jul 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- PFIZER INC.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20253 payments
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2018–2026 per NIH RePORTER. The latest:
Congress activity
Updated 14 Jul 2026
97 congress contributions (2008–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A personalized neoantigen vaccine to reprogram the immune landscape of glioblastoma.
ASCO Annual Meeting
ASCO2026Co-author - Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Sensitive detection of cancer antigens enabled by user-defined peptide libraries.
Nature biotechnology
2026
Most-cited worksby citation count (OpenAlex)
- 01An immunogenic personal neoantigen vaccine for patients with melanoma2,931 citations2017
- 02Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma2,764 citations2015
- 03
- 04
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
450 Brookline Avenue, Boston, MA 02215
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- MD
PhD - Ludwig Maximilians University of Munich, Germany
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗ - Residency
Internal Medicine - Case Western Reserve University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗ - Fellowship
Hematology-Oncology - New York University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
Editorial & leadership rolesjournal and society appointments
- Principal Investigator
first-in-human personalized neoantigen vaccine (NeoVax) trial in melanoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗ - Member
ASCO, AACR, ESMO, SITC (professional/society memberships)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksmoconference.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliationsappointments beyond the home institution
- Attending Physician
Department of Medicine, Brigham and Women's Hospital, Boston, MA
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com ↗ - Director
Center for Cancer Vaccines, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →statnews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/patrick-ott-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_melanoma-vaccine-progress-and-possibility-activity-7158156922917982209-QVml
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Nikhil Munshi, MD
Dana-Farber Cancer Institute
- 1,801
- publications
- 152
- h-index
- 8
- trials
Patrick Wen, MD
Dana-Farber Cancer Institute
- 1,915
- publications
- 146
- h-index
- 27
- trials
Geoffrey Shapiro, MD
Dana-Farber Cancer Institute
- 2,055
- publications
- 116
- h-index
- 24
- trials
Irene Ghobrial, MD
Dana-Farber Cancer Institute
- 1,124
- publications
- 101
- h-index
- 16
- trials